Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 21 |
| List of Tables | 19 | 3 |
| List of Figures | 22 | 1 |
| Introduction | 23 | 1 |
| Global Markets Direct Report Coverage | 23 | 1 |
| Head And Neck Cancer Squamous Cell Carcinoma Overview | 24 | 1 |
| Therapeutics Development | 25 | 2 |
| Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma Overview | 25 | 1 |
| Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma Comparative Analysis | 26 | 1 |
| Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Development by Companies | 27 | 7 |
| Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Investigation by Universities/Institutes | 34 | 1 |
| Head And Neck Cancer Squamous Cell Carcinoma Pipeline Products Glance | 35 | 4 |
| Late Stage Products | 35 | 1 |
| Clinical Stage Products | 36 | 1 |
| Early Stage Products | 37 | 1 |
| Unknown Stage Products | 38 | 1 |
| Head And Neck Cancer Squamous Cell Carcinoma Products under Development by Companies | 39 | 10 |
| Head And Neck Cancer Squamous Cell Carcinoma Products under Investigation by Universities/Institutes | 49 | 1 |
| Head And Neck Cancer Squamous Cell Carcinoma Companies Involved in Therapeutics Development | 50 | 85 |
| AB Science SA | 50 | 1 |
| AbbVie Inc | 51 | 1 |
| Accelerated Pharma, Inc. | 52 | 1 |
| Acceleron Pharma, Inc. | 53 | 1 |
| Adaptimmune Therapeutics Plc | 54 | 1 |
| Advaxis, Inc. | 55 | 1 |
| Altor BioScience Corporation | 56 | 1 |
| Amgen Inc. | 57 | 1 |
| AstraZeneca Plc | 58 | 1 |
| AVEO Pharmaceuticals, Inc. | 59 | 1 |
| Bayer AG | 60 | 1 |
| Bionovis SA | 61 | 1 |
| BioNTech AG | 62 | 1 |
| Boehringer Ingelheim GmbH | 63 | 1 |
| Bristol-Myers Squibb Company | 64 | 1 |
| Calithera Biosciences, Inc. | 65 | 1 |
| CEL-SCI Corporation | 66 | 1 |
| Cellceutix Corporation | 67 | 1 |
| Celldex Therapeutics, Inc. | 68 | 1 |
| Centrose LLC | 69 | 1 |
| Critical Outcome Technologies Inc. | 70 | 1 |
| CytImmune Sciences, Inc. | 71 | 1 |
| Daiichi Sankyo Company, Limited | 72 | 1 |
| Eisai Co., Ltd. | 73 | 1 |
| Eleven Biotherapeutics Inc. | 74 | 1 |
| Eli Lilly and Company | 75 | 1 |
| Etubics Corporation | 76 | 1 |
| F. Hoffmann-La Roche Ltd. | 77 | 1 |
| G&E Herbal Biotechnology Co., Ltd. | 78 | 1 |
| GeneSegues Inc | 79 | 1 |
| Genexine, Inc. | 80 | 1 |
| Genmab A/S | 81 | 1 |
| GlaxoSmithKline Plc | 82 | 1 |
| Gliknik, Inc. | 83 | 1 |
| Glycotope GmbH | 84 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 85 | 1 |
| Horizon Pharma Plc | 86 | 1 |
| Immunomedics, Inc. | 87 | 1 |
| Immunovative Therapies, Ltd. | 88 | 1 |
| Incyte Corporation | 89 | 1 |
| Infinity Pharmaceuticals, Inc. | 90 | 1 |
| Innate Pharma S.A. | 91 | 1 |
| Inovio Pharmaceuticals, Inc. | 92 | 1 |
| IRX Therapeutics, Inc. | 93 | 1 |
| Johnson &Johnson | 94 | 1 |
| Kolltan Pharmaceuticals, Inc. | 95 | 1 |
| Laboratoires Pierre Fabre SA | 96 | 1 |
| Loxo Oncology, Inc. | 97 | 1 |
| Mabion SA | 98 | 1 |
| MacroGenics, Inc. | 99 | 1 |
| Marsala Biotech Inc. | 100 | 1 |
| Mateon Therapeutics Inc | 101 | 1 |
| MedImmune LLC | 102 | 1 |
| Merck &Co., Inc. | 103 | 1 |
| Merck KGaA | 104 | 1 |
| Merrimack Pharmaceuticals, Inc. | 105 | 1 |
| Millennium Pharmaceuticals Inc | 106 | 1 |
| Mirati Therapeutics Inc. | 107 | 1 |
| Molecular Partners AG | 108 | 1 |
| Molplex Ltd. | 109 | 1 |
| NanoCarrier Co., Ltd. | 110 | 1 |
| Novartis AG | 111 | 1 |
| Oncobiologics, Inc. | 112 | 1 |
| Oncolytics Biotech Inc. | 113 | 1 |
| Onconova Therapeutics, Inc. | 114 | 1 |
| OncoSec Medical Incorporated | 115 | 1 |
| Ono Pharmaceutical Co., Ltd. | 116 | 1 |
| Panacea Biotec Limited | 117 | 1 |
| PCI Biotech Holding ASA | 118 | 1 |
| Pfizer Inc. | 119 | 1 |
| Reliance Life Sciences Pvt. Ltd. | 120 | 1 |
| Sanofi | 121 | 1 |
| Shanghai Henlius Biotech Co., Ltd. | 122 | 1 |
| Shionogi &Co., Ltd. | 123 | 1 |
| Sillajen Biotherapeutics | 124 | 1 |
| Symphogen A/S | 125 | 1 |
| SynCore Biotechnology Co., Ltd. | 126 | 1 |
| Takara Bio Inc. | 127 | 1 |
| Tara Immuno-Oncology Therapeutics LLC | 128 | 1 |
| Transgene SA | 129 | 1 |
| UbiVac, LLC | 130 | 1 |
| VasGene Therapeutics, Inc. | 131 | 1 |
| VentiRx Pharmaceuticals, Inc. | 132 | 1 |
| Virttu Biologics Limited | 133 | 1 |
| Vyriad Inc | 134 | 1 |
| Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Assessment | 135 | 30 |
| Assessment by Monotherapy Products | 135 | 1 |
| Assessment by Combination Products | 136 | 1 |
| Assessment by Target | 137 | 12 |
| Assessment by Mechanism of Action | 149 | 12 |
| Assessment by Route of Administration | 161 | 2 |
| Assessment by Molecule Type | 163 | 2 |
| Drug Profiles | 165 | 534 |
| ABBV-221 Drug Profile | 165 | 1 |
| acalabrutinib Drug Profile | 166 | 3 |
| AdIL-24 Drug Profile | 169 | 2 |
| afatinib dimaleate Drug Profile | 171 | 13 |
| AlloVax Drug Profile | 184 | 2 |
| alpelisib Drug Profile | 186 | 3 |
| ALT-803 Drug Profile | 189 | 3 |
| AMG-319 Drug Profile | 192 | 1 |
| Antibodies to Inhibit FRMD4A for Oncology Drug Profile | 193 | 1 |
| Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 194 | 1 |
| AV-203 Drug Profile | 195 | 3 |
| avelumab Drug Profile | 198 | 6 |
| axalimogene filolisbac Drug Profile | 204 | 16 |
| AZD-1775 Drug Profile | 220 | 3 |
| AZD-6738 Drug Profile | 223 | 1 |
| AZD-9150 Drug Profile | 224 | 3 |
| BMS-986016 Drug Profile | 227 | 2 |
| BNV-003 Drug Profile | 229 | 1 |
| buparlisib hydrochloride Drug Profile | 230 | 5 |
| cabazitaxel Drug Profile | 235 | 2 |
| capmatinib Drug Profile | 237 | 3 |
| CB-1158 Drug Profile | 240 | 2 |
| Cellular Immunotherapy for Oncology Drug Profile | 242 | 1 |
| Cellular Immunotherapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 243 | 1 |
| Cellular Immunotherapy to Target MAGE-A10 for Oncology Drug Profile | 244 | 2 |
| cetuximab Drug Profile | 246 | 6 |
| cetuximab biobetter Drug Profile | 252 | 2 |
| cetuximab biosimilar Drug Profile | 254 | 1 |
| cetuximab biosimilar Drug Profile | 255 | 1 |
| cetuximab biosimilar Drug Profile | 256 | 1 |
| cetuximab biosimilar Drug Profile | 257 | 1 |
| cetuximab biosimilar Drug Profile | 258 | 1 |
| cetuximab biosimilar Drug Profile | 259 | 1 |
| cisplatin Drug Profile | 260 | 2 |
| copanlisib hydrochloride Drug Profile | 262 | 4 |
| COTI-2 Drug Profile | 266 | 8 |
| CYT-6091 Drug Profile | 274 | 2 |
| dalantercept Drug Profile | 276 | 4 |
| Debio-1143 Drug Profile | 280 | 3 |
| depatuxizumab Drug Profile | 283 | 1 |
| DNA IL-12 Drug Profile | 284 | 8 |
| DPV-001 Drug Profile | 292 | 2 |
| DTP-348 Drug Profile | 294 | 1 |
| durvalumab Drug Profile | 295 | 11 |
| durvalumab + tremelimumab Drug Profile | 306 | 4 |
| E-10A Drug Profile | 310 | 1 |
| E-7046 Drug Profile | 311 | 1 |
| EBC-46 Drug Profile | 312 | 1 |
| EDC-2 Drug Profile | 313 | 1 |
| EDE-1409 Drug Profile | 314 | 1 |
| enoblituzumab Drug Profile | 315 | 2 |
| epacadostat Drug Profile | 317 | 5 |
| ETBX-041 Drug Profile | 322 | 1 |
| everolimus Drug Profile | 323 | 11 |
| ficlatuzumab Drug Profile | 334 | 3 |
| futuximab + modotuximab Drug Profile | 337 | 3 |
| ganetespib Drug Profile | 340 | 12 |
| gedatolisib Drug Profile | 352 | 2 |
| Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma Drug Profile | 354 | 1 |
| GL-0817 Drug Profile | 355 | 1 |
| glesatinib Drug Profile | 356 | 5 |
| golvatinib tartrate Drug Profile | 361 | 2 |
| GS-10 Drug Profile | 363 | 2 |
| GSK-2636771 Drug Profile | 365 | 1 |
| GSK-2849330 Drug Profile | 366 | 1 |
| GSK-3174998 Drug Profile | 367 | 1 |
| GX-051 Drug Profile | 368 | 1 |
| HF-10 Drug Profile | 369 | 2 |
| HSV-1716 Drug Profile | 371 | 3 |
| human papillomavirus [serotypes 16] vaccine Drug Profile | 374 | 1 |
| HylaPlat Drug Profile | 375 | 1 |
| IC-1001 Drug Profile | 376 | 1 |
| INCB-50465 Drug Profile | 377 | 1 |
| INO-1400 Drug Profile | 378 | 1 |
| INO-3106 Drug Profile | 379 | 1 |
| INO-3112 Drug Profile | 380 | 2 |
| interferon gamma-1b Drug Profile | 382 | 4 |
| IPI-549 Drug Profile | 386 | 2 |
| ipilimumab Drug Profile | 388 | 9 |
| IRX-2 Drug Profile | 397 | 2 |
| itacitinib adipate Drug Profile | 399 | 3 |
| JS-001 Drug Profile | 402 | 1 |
| JX-929 Drug Profile | 403 | 1 |
| Kevetrin Drug Profile | 404 | 11 |
| KGP-94 Drug Profile | 415 | 1 |
| KTN-3379 Drug Profile | 416 | 4 |
| lenvatinib mesylate Drug Profile | 420 | 13 |
| Leukocyte Interleukin Drug Profile | 433 | 14 |
| LGK-974 Drug Profile | 447 | 1 |
| lirilumab Drug Profile | 448 | 4 |
| LN-145 Drug Profile | 452 | 2 |
| LOXO-101 Drug Profile | 454 | 4 |
| lumretuzumab Drug Profile | 458 | 2 |
| masitinib Drug Profile | 460 | 14 |
| MEDI-0562 Drug Profile | 474 | 2 |
| merestinib Drug Profile | 476 | 2 |
| MGD-009 Drug Profile | 478 | 2 |
| MIR-101 Drug Profile | 480 | 1 |
| monalizumab Drug Profile | 481 | 4 |
| Monoclonal Antibody to Target CD147 for Pancreatic Adenocarcinoma and Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 485 | 1 |
| motolimod Drug Profile | 486 | 3 |
| MP-0250 Drug Profile | 489 | 1 |
| nilotinib Drug Profile | 490 | 6 |
| nimotuzumab Drug Profile | 496 | 4 |
| nivolumab Drug Profile | 500 | 33 |
| NIZ-985 Drug Profile | 533 | 1 |
| NP-001 Drug Profile | 534 | 1 |
| olaparib Drug Profile | 535 | 9 |
| Oncolytic Virus 1 to Target CD46 for Oncology Drug Profile | 544 | 1 |
| Oncolytic Virus to Activate IFN-b for Hepatocellular Carcinoma and Head And Neck Cancer Squamous Cell Carcinoma Drug Profile | 545 | 1 |
| palbociclib Drug Profile | 546 | 11 |
| panitumumab Drug Profile | 557 | 5 |
| patritumab Drug Profile | 562 | 2 |
| pelareorep Drug Profile | 564 | 14 |
| pembrolizumab Drug Profile | 578 | 37 |
| PF-04518600 Drug Profile | 615 | 1 |
| PF-06801591 Drug Profile | 616 | 1 |
| picoplatin Drug Profile | 617 | 3 |
| poziotinib Drug Profile | 620 | 2 |
| prexasertib Drug Profile | 622 | 2 |
| QR-206 Drug Profile | 624 | 1 |
| Recombinant Peptide to Target EGFR for Oncology Drug Profile | 625 | 1 |
| Recombinant Protein for Oncology Drug Profile | 626 | 1 |
| rigosertib sodium Drug Profile | 627 | 10 |
| S-488210 Drug Profile | 637 | 1 |
| sacituzumab Drug Profile | 638 | 8 |
| SB-01 Drug Profile | 646 | 1 |
| seribantumab Drug Profile | 647 | 7 |
| SF-1126 Drug Profile | 654 | 2 |
| Small Molecules for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 656 | 1 |
| Small Molecules to Antagonize Endothelin B Receptor for Oncology Drug Profile | 657 | 1 |
| Small Molecules to Inhibit 16S rRNA for Head And Neck Cancer Squamous Cell Carcinoma, Malaria and Oral Cancer Drug Profile | 658 | 1 |
| Small Molecules to Inhibit CREB Protein for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 659 | 1 |
| Small Molecules to Inhibit IL-6 for Head and Neck Squamous Cell Carcinoma Drug Profile | 660 | 1 |
| solarise Drug Profile | 661 | 1 |
| Synthetic Peptide for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile | 662 | 1 |
| TAK-659 Drug Profile | 663 | 1 |
| talimogene laherparepvec Drug Profile | 664 | 6 |